Table 3.
GMCs with 95% CIs measured in infants at delivery in total parent population (only 544 infants had information about antibody titers at delivery available) and study groups by aim.
| Anti-PT | Anti-FHA | Anti-PRN | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Parent Population | Aim 1 | Aim 2 | Parent Population | Aim 1 | Aim 2 | Parent Population | Aim 1 | Aim 2 | |
| n | 544 | 475 | 541 | 544 | 474 | 541 | 544 | 474 | 541 |
| GMC (95% CI) | 3.99 (3.90-4.07) |
4.01 (3.91-4.10) |
3.99 (3.90-4.08) |
5.61 (5.51-5.71) |
5.70 (5.59-5.80) |
5.61 (5.51-5.71) |
5.26 (5.10-5.41) |
5.28 (5.11-5.44) |
5.26 (5.11-5.41) |
*GMCs are expressed in IU/mL (BE1, VN1, TL1) or EU/mL (BE2, BE3), n = number of observations. PT, Pertussis Toxin; FHA, Filamentous Hemagglutinin; PRN, Pertactin. Aim 1: determine the effect of GAV on cord blood antibody titers in term born infants; Aim 2: determine the effect of the interval between GAV and GAD on cord blood antibody titers in term and preterm born infants). GMCs are expressed in IU/mL (BE1, VN1, TL1) or EU/mL (BE2, BE3), n = number of observations.